← Human Trials & Peer-Reviewed Studies
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial
Plain-language guide to PMID 29316130 (2018): double-blind randomized controlled trial study of Insulin Aspart and Insulin Detemir.
Key Facts
- PMID
- 29316130
- Journal
- Diabetes, obesity & metabolism
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Mathieu C et al. (8 authors)
- DOI
- 10.1111/dom.13205
- Registered trial
- NCT01831765
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Aspart and Insulin Detemir, published as a randomized controlled trial.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Adults with T1D were randomly allocated to double-blind mealtime faster aspart or IAsp, each with once- or twice-daily insulin detemir.
How the Study Was Run
In design terms this was a randomized, double-blind and multicenter study.
Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.
More than one site took part, so the participants came from several places.
Onset 1 was a randomized, multicentre, treat-to-target, phase III, 52-week (initial 26 weeks + additional 26 weeks) trial conducted at 165 sites across 9 countries.
The primary endpoint, change in glycated haemoglobin (HbA1c) from baseline after the initial 26 weeks, has been reported previously.
In the present paper, the researchers report data from the full 52-week study period.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Drug Compounding, Drug Monitoring, Glycated Hemoglobin and Hyperglycemia.
Author keywords: insulin therapy and type 1 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Insulin Aspart and Insulin Detemir.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Insulin Aspart compound page and the Insulin Detemir compound page.
Our Notes on the Compounds
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.